Study aim: 1. Evaluation of the therapeutic effect of colchicine plus chloroquine in comparison with chloroquine in patients with COVID-19 In terms of the outcome including mortality, transference to ICU and discharge 2. Evaluation of the therapeutic effect of colchicine plus chloroquine in comparison with chloroquine in patients with COVID-19 In terms of the hospitalization duration 3. Evaluation of the therapeutic effect of colchicine plus chloroquine in comparison with chloroquine in patients with COVID-19 In terms of the cessation of fever Design: clinical trial, blinded, phase III, with control group, 100 patients divided into 2 groups, randomized using random number table. Settings and conduct: This blinded clinical trial will be done in Imam Reza hospital of Ardabil on 100 COVID19 patients divided into 2 groups. the participants will be blinded to their regimen. Participants/Inclusion and exclusion criteria: Inclusion criteria: 1. Pulmonary involvement seen in CT-Scan compatible with COVID19 2. Positive PCR of COVID19 Exclusion criteria: 1. Sensitivity to any medications of regimen 2. Renal failure 3.Heart diseas 4. Pregnancy 5. Reluctance to participate in the study Intervention groups: Individuals of intervention group will receive 1 mg tablet of colchicine daily. The participants of the placebo group will receive a similar tablet without therapeutic effects. Main outcome variables: Hospitalization duration; cessation of fever; outcome including mortality; transference to ICU and discharge